Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.18
SLXP's Cash to Debt is ranked lower than
88% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. SLXP: 0.18 )
Ranked among companies with meaningful Cash to Debt only.
SLXP' s 10-Year Cash to Debt Range
Min: 0.18  Med: 5064.58 Max: No Debt
Current: 0.18
Equity to Asset 0.06
SLXP's Equity to Asset is ranked lower than
98% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SLXP: 0.06 )
Ranked among companies with meaningful Equity to Asset only.
SLXP' s 10-Year Equity to Asset Range
Min: 0.06  Med: 0.70 Max: 0.89
Current: 0.06
0.06
0.89
F-Score: 4
Z-Score: 1.34
M-Score: -2.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -43.24
SLXP's Operating margin (%) is ranked lower than
87% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. SLXP: -43.24 )
Ranked among companies with meaningful Operating margin (%) only.
SLXP' s 10-Year Operating margin (%) Range
Min: -511.93  Med: -23.97 Max: 27.61
Current: -43.24
-511.93
27.61
Net-margin (%) -36.60
SLXP's Net-margin (%) is ranked lower than
86% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. SLXP: -36.60 )
Ranked among companies with meaningful Net-margin (%) only.
SLXP' s 10-Year Net-margin (%) Range
Min: -475.24  Med: -23.55 Max: 16.17
Current: -36.6
-475.24
16.17
ROE (%) -70.99
SLXP's ROE (%) is ranked lower than
90% of the 696 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. SLXP: -70.99 )
Ranked among companies with meaningful ROE (%) only.
SLXP' s 10-Year ROE (%) Range
Min: -102  Med: -17.06 Max: 20.29
Current: -70.99
-102
20.29
ROA (%) -9.69
SLXP's ROA (%) is ranked lower than
78% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.32 vs. SLXP: -9.69 )
Ranked among companies with meaningful ROA (%) only.
SLXP' s 10-Year ROA (%) Range
Min: -77.4  Med: -11.78 Max: 10.41
Current: -9.69
-77.4
10.41
ROC (Joel Greenblatt) (%) -114.47
SLXP's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. SLXP: -114.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SLXP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7190.09  Med: -215.82 Max: 164.49
Current: -114.47
-7190.09
164.49
Revenue Growth (3Y)(%) 29.30
SLXP's Revenue Growth (3Y)(%) is ranked higher than
89% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. SLXP: 29.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SLXP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2  Med: 33.20 Max: 112.5
Current: 29.3
-2
112.5
» SLXP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SLXP Guru Trades in Q3 2014

Paul Tudor Jones 12,629 sh (+601.61%)
Andreas Halvorsen 3,195,153 sh (+10.59%)
Pioneer Investments 374,220 sh (unchged)
Andreas Halvorsen 2,719,538 sh (-5.88%)
Vanguard Health Care Fund 1,538,045 sh (-15.70%)
Steven Cohen 150,000 sh (-71.58%)
Jim Simons 44,525 sh (-82.73%)
» More
Q4 2014

SLXP Guru Trades in Q4 2014

George Soros 491,531 sh (New)
Louis Moore Bacon 10,000 sh (New)
Jana Partners 1,120,921 sh (New)
John Paulson 5,806,000 sh (New)
Paul Tudor Jones 50,400 sh (+299.08%)
Steven Cohen 502,500 sh (+235.00%)
Jana Partners 738,000 sh (unchged)
Andreas Halvorsen 1,738,104 sh (unchged)
Vanguard Health Care Fund Sold Out
Jim Simons 41,419 sh (-6.98%)
Andreas Halvorsen 1,738,104 sh (-36.09%)
Pioneer Investments 167,884 sh (-55.14%)
» More
Q1 2015

SLXP Guru Trades in Q1 2015

Ruane Cunniff 20,000 sh (New)
Eric Mindich 607,983 sh (New)
Mario Gabelli 442,350 sh (New)
First Eagle Investment 479,891 sh (New)
Jim Simons 840,943 sh (+1930.33%)
Steven Cohen 5,000 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
Jana Partners Sold Out
Louis Moore Bacon Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
John Paulson 5,500,000 sh (-5.27%)
George Soros 201,903 sh (-58.92%)
Pioneer Investments 36,771 sh (-78.10%)
» More
Q2 2015

SLXP Guru Trades in Q2 2015

John Paulson Sold Out
Mario Gabelli Sold Out
Pioneer Investments Sold Out
First Eagle Investment Sold Out
Eric Mindich Sold Out
Ruane Cunniff Sold Out
Jim Simons Sold Out
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SLXP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Salix Pharmaceuticals Ltd

Ruane Cunniff Adds New Positions to Portfolio In Q1FY15
Ruane Cunniff (Trades, Portfolio) added six new positions to his portfolio during 1QFY15, which leaves him with a total of 155 stocks that are valued around $21.12 billion, and have a quarter over quarter turnover of 1%. Over half of his portfolio consists of stocks in the healthcare sector. Read more...
John Paulson's Top Buys
John Paulson (Trades, Portfolio) of Paulson & Co added new positions to his portfolio of 63 stocks with a value of $19.362 billion and a quarter over quarter turnover rate of 11%. Read more...
John Paulson Chooses Energy, Semiconductor and Drug Stocks in Q4
John Paulson (Trades, Portfolio) made a record Wall Street $5 billion payday in 2010 but has had some tough years since then. Read more...

Ratios

vs
industry
vs
history
Forward P/E 19.23
SLXP's Forward P/E is ranked higher than
60% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. SLXP: 19.23 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 46.21
SLXP's P/B is ranked lower than
99% of the 644 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. SLXP: 46.21 )
Ranked among companies with meaningful P/B only.
SLXP' s 10-Year P/B Range
Min: 1.04  Med: 5.16 Max: 46.21
Current: 46.21
1.04
46.21
P/S 10.22
SLXP's P/S is ranked lower than
82% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.13 vs. SLXP: 10.22 )
Ranked among companies with meaningful P/S only.
SLXP' s 10-Year P/S Range
Min: 1.28  Med: 4.98 Max: 10.22
Current: 10.22
1.28
10.22
Current Ratio 0.68
SLXP's Current Ratio is ranked lower than
96% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. SLXP: 0.68 )
Ranked among companies with meaningful Current Ratio only.
SLXP' s 10-Year Current Ratio Range
Min: 0.68  Med: 3.59 Max: 8.94
Current: 0.68
0.68
8.94
Quick Ratio 0.56
SLXP's Quick Ratio is ranked lower than
93% of the 617 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. SLXP: 0.56 )
Ranked among companies with meaningful Quick Ratio only.
SLXP' s 10-Year Quick Ratio Range
Min: 0.56  Med: 2.98 Max: 8.94
Current: 0.56
0.56
8.94
Days Inventory 155.38
SLXP's Days Inventory is ranked lower than
69% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.66 vs. SLXP: 155.38 )
Ranked among companies with meaningful Days Inventory only.
SLXP' s 10-Year Days Inventory Range
Min: 107.26  Med: 199.92 Max: 367.23
Current: 155.38
107.26
367.23
Days Sales Outstanding 13.69
SLXP's Days Sales Outstanding is ranked higher than
92% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.39 vs. SLXP: 13.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
SLXP' s 10-Year Days Sales Outstanding Range
Min: 13.69  Med: 81.72 Max: 154.51
Current: 13.69
13.69
154.51

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 7.43
SLXP's Price/Projected FCF is ranked lower than
81% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. SLXP: 7.43 )
Ranked among companies with meaningful Price/Projected FCF only.
SLXP' s 10-Year Price/Projected FCF Range
Min: 3.33  Med: 5.72 Max: 76.06
Current: 7.43
3.33
76.06
Price/Median PS Value 2.05
SLXP's Price/Median PS Value is ranked lower than
77% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.28 vs. SLXP: 2.05 )
Ranked among companies with meaningful Price/Median PS Value only.
SLXP' s 10-Year Price/Median PS Value Range
Min: 0.33  Med: 1.16 Max: 3.14
Current: 2.05
0.33
3.14
Earnings Yield (Greenblatt) (%) -3.70
SLXP's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. SLXP: -3.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SLXP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -3.7  Med: 4.00 Max: 9.7
Current: -3.7
-3.7
9.7

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 1,301 1,949 2,396
EPS($) 3.67 8.98 9.30
EPS without NRI($) 3.67 8.98 9.30

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:XP2.Germany,
Salix Pharmaceuticals Ltd was incorporated in Delaware. The Company is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of gastrointestinal diseases, which are affecting the digestive tract. Its search and development efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal disease that have an existing base of safety and efficacy data. Its products include APRISO, the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Another product, COLAZAL, treats mildly to moderately active ulcerative colitis, a form of inflammatory bowel disease. XIFAXAN is a nonsystemic antibiotic that treats travelers' diarrhea caused by noninvasive E. coli. PEPCID treats active duodenal ulcer, active benign gastric ulcer, and gastroesophageal reflux disease (GERD). OsmoPrep consists of a series of pills taken with the clear liquid. MoviPrep is a tolerable, lowvolume liquid bowel prep with the effectiveness of highvolume prep. VISICOL, the precursor to OsmoPrep, this colonoscopy preparation also features a regimen of tablets taken with any clear liquid. AnusolHC and PROCTOCORT provide soothing relief from anal itching, burning, and inflammation. AZASAN prevents rejection of kidney transplant and provides therapy for the management of severe active rheumatoid arthritis. Diuril treats high blood pressure and is an adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney disease. The Company mainly sells its products to pharmaceutical wholesalers. The Company uses third party manufacturers to produce its products. The research, testing, manufacture, marketing and distribution of drug products are extensively regulated by governmental authorities in the United States and other countries.
» More Articles for SLXP

Headlines

Articles On GuruFocus.com
First Eagle Fund Of America 2Q Commentary Aug 11 2015 
Ruane Cunniff Adds New Positions to Portfolio In Q1FY15 May 18 2015 
Locust Wood Capital Bet on Top Performer Valeant Pharmaceuticals May 14 2015 
Jean-Marie Eveillard Buys Flowserve, W W Grainger May 11 2015 
Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
This Week’s Pharma Highlights Mar 19 2015 
Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
Valeant Pharma Acquires Salix Mar 18 2015 
Looking Ahead of Wall Street: Salix Pharmaceuticals, Receptos, Tetraphase Mar 02 2015 
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 

More From Other Websites
Why Valeant's acquisition of Sprout could play out differently than Salix deal Aug 20 2015
Valeant Pharmaceuticals (VRX) Earnings Report: Q2 2015 Conference Call Transcript Jul 23 2015
Valeant profit beats estimates as U.S. sales stay strong Jul 23 2015
Owners of prominent Raleigh office building to test crowdfunding for real estate Jul 15 2015
Valeant Shouldn’t Overfarm Deal Field Jun 26 2015
Raleigh's BioDelivery hires former Salix sales workers May 29 2015
Valeant Pharmaceuticals Gets FDA Nod for Xifaxan for IBS-D - Analyst Blog May 28 2015
After Salix acquisition, Valeant receives FDA approval for IBS-D drug May 27 2015
Ruane Cunniff Adds New Positions to Portfolio In Q1FY15 May 18 2015
More Waves In Pharma: Endo Buys TPG Capital's Par Pharma for $8 Billion May 18 2015
John Paulson Buys Actavis, AIG, Valeant, Sells Equinix, Alibaba May 16 2015
Big name investors take sides on Ackman bet on Valeant: filings May 15 2015
JetBlue Airways Corporation (JBLU), Twenty-First Century Fox Inc (FOX): CQS Cayman’s Top Picks for... May 14 2015
Viking Global's Shareholder Letter Talks New Positions In Google, Cheniere, Biggest Winners & Losers May 01 2015
Valeant Pharmaceuticals Reports In-Line Earnings, Ups View - Analyst Blog May 01 2015
Valeant Pharmaceuticals (VRX) Earnings Report: Q1 2015 Conference Call Transcript Apr 30 2015
Valeant Beats Q1 Views, Lifts Guidance, Loses CFO Apr 29 2015
Valeant raises outlook after completing purchase of Salix Apr 29 2015
Valeant raises outlook after completing purchase of Salix Apr 29 2015
Valeant Profit Tops Analysts’ Estimates as Drug Sales Surge Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK